International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry
NCT ID: NCT04738071
Last Updated: 2024-03-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
3730 participants
OBSERVATIONAL
2019-11-13
2025-11-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The IMPROVE (International Multicenter Patent foRamen OVale \& strokE) Registry is an observational, multicenter, international registry of men and women with an ischemic stroke or TIA. The aim is to enroll 8,800 patient-years at ≥50 sites in ≥20 countries.
The IMPROVE Registry will provide important information about the management and related outcomes of patients with ischemic stroke or TIA and PFO throughout different regions of the world and across a wide spectrum of healthcare systems.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Atrial Fibrillation in Cryptogenic Stroke With Patent Foramen Ovale Closure (PFO-AF) Study
NCT04926142
The Effect of Pulse Field Ablation on Atrial Mechanics in Catheter Ablation of Paroxysmal Atrial Fibrillation
NCT06557876
Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation
NCT04497376
Pulmonary Vein Isolation in Typical Atrial Flutter and Heart Failure
NCT06817447
Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease
NCT06969378
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sex
Female and male patients
PFO closure
PFO closure after stroke or transient ischemic attack
Age >60 years of age
Patients younger or oder than 6o years of age
PFO closure
PFO closure after stroke or transient ischemic attack
World region
Patients from different world regions: North America, Europe, Asia, Latin America
PFO closure
PFO closure after stroke or transient ischemic attack
Stroke vs. TIA
Index event: stroke vs. TIA
PFO closure
PFO closure after stroke or transient ischemic attack
Neurocardiology Teams
Patients assessed by a neurocardiology team
PFO closure
PFO closure after stroke or transient ischemic attack
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PFO closure
PFO closure after stroke or transient ischemic attack
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ischemic stroke or TIA within 5 years and 1 year before inclusion in the registry. Patients with cerebrovascular events occurred within one year before the inclusion in the registry should be part of the prospective cohort.
* Ischemic stroke is defined as:
* focal neurological deficit of central origin lasting ≥24 hours -except for death within 24hrs- with or without imaging confirmation of cerebral infarction; or
* focal neurological deficit of central origin lasting \<24 hours with corresponding imaging evidence of cerebral infarction; or
* focal neurological deficit of central origin lasting \<24 hours in patients receiving IV thrombolysis or endovascular thrombectomy with or without imaging confirmation of cerebral infarction; or
* non-focal encephalopathy lasting more than 24 hours -except for death within 24hrs- with imaging evidence of cerebral infarction; or
* acute and permanent retinal ischemia of arterial origin.
* TIA is defined as:
* focal neurological deficit of central origin lasting \<24 hours without corresponding imaging evidence of cerebral infarction in patients not receiving IV thrombolysis or endovascular thrombectomy.
* Confirmed patent foramen ovale.
Exclusion Criteria
* Venous stroke
* Stroke mimics
* Patients with incomplete data at 12 months after the index ischemic stroke or TIA.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luciano A Sposato, MD, MBA (PI)
Role: PRINCIPAL_INVESTIGATOR
London Health Sciences Centre, Western University (London, ON. Canada)
Antonio Arauz, MD (Co-Pi)
Role: PRINCIPAL_INVESTIGATOR
National Institute of Neurology and Neurosurgery Manuel Velasco Suárez
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart & Brain Lab, Western University
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R-19-597
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.